2026-05-17T05:46:38Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/233122024-11-29T00:32:29Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Herraez Balanzat, Ines author Bento, Leyre author Daumal-Domenech, Jaume author Repetto, Alessandra author del Campo Garcia, Raquel author Perez, Sandra author Ramos, Rafael author Ibarra, Javier author Mestre, Francesc author Bargay Lleonart, Joan author Lopez, Paloma author Garcias-Ladaria, Joan author Sampol Mayol, Antonia author Gutierrez, Antonio author 2021-10 Hodgkin lymphoma (HL) is a hematological malignancy with an excellent prognosis. However, we still need to identify those patients that could experience failed standard frontline chemotherapy. Tumor burden evaluation and standard decisions are based on Ann Arbor (AA) staging, but this approach may be insufficient in predicting outcomes. We aim to study new ways to assess tumor burden through volume-based PET parameters to improve the risk assessment of HL patients. We retrospectively analyzed 101 patients with HL from two hospitals in the Balearic Islands between 2011 and 2018. Higher metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were significantly associated with a higher incidence of III-IV AA stages, B-symptoms, hypoalbuminemia, lymphopenia, and higher IPS. Standardized uptake value (SUVmax) was significantly related to AA stage and hypoalbuminemia. We found that TLG or the combination of SUVmax, TLG, and MTV significantly improved the risk assessment when compared to AA staging. We conclude that TLG is the best single PET/CT-related tumor-load parameter that significantly improves HL risk assessment when compared to AA staging. If confirmed in a larger and validated sample, this information could be used to modify standard frontline therapy and justifies the inclusion of TLG inside an HL prognostic score. Herraez I, Bento L, Daumal J, Repetto A, Del Campo R, Perez S, et al. Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma. J Clin Med. 2021 Oct;10(19):4396. 10.3390/jcm10194396 2077-0383 Journal of Clinical Medicine https://hdl.handle.net/20.500.13003/19880 34640418 L2013895213 2-s2.0-85115791117 https://hdl.handle.net/20.500.12105/23312 707382400001 Hodgkin lymphoma Ann Arbor stage Metabolic tumor volume Total lesion glycolysis Risk assessment Survival Total Lesion Glycolysis Improves Tumor Burden Evaluation and Risk Assessment at Diagnosis in Hodgkin Lymphoma